第二型糖尿病患者口服抑制二肽基酶(DPP-4) 酵素藥物療效的分析

Effect Of Oral DPP-4 Inhibitor Treatment To Type 2 Diabetic Patients

陳瑞明(CHEN RUI MING)

指導教授 ： 李桂仁

亞洲大學/資訊學院/生物資訊學系碩士在職專班/碩士(2009年)

摘要

尿病至少影響全球兩億人的健康情況，全世界每十秒鐘就有一人死於糖尿病。IDF 預期到二零二五年，會增加到三億三千三百萬人。在台灣部分衛生署公布98年死因統計報告糖尿病至今已成為國人十大死因的第五位佔總體死亡率的5.8%(台灣衛生署，2009)，糖尿病已成為國人的慢性病之一，糖尿病若控制不良會造成許多的併發症。
最新引進國內之口服降血糖藥二肽基酶-4 抑制劑（Dipeptidyl Peptidase-IV Inhibitor），為pyrrolidine 的衍生物，可抑制DPP IV的活性， 避免內生性GLP-1 （ glucagon-likepeptide-1 ） 及GIP （ glucose-dependent insulinotropic polypeptide）被分解
而達到有效降低過高血糖,不影響體重,且不易引起血糖過低。
本臨床研究於中部某區域醫院進行,共收入49位病人,經投與口服DPP-4抑制劑(Sitagliptin),三個月後,分析糖化血色素, 及飯前血糖,體重三個月前後之變化,初步證明此藥物於國人糖尿病患者中,亦能發揮其療效與安全性，此研究結果可為國人臨床糖尿病治療之參考

關鍵字

糖尿病 ； 二肽基酶-4抑制劑 ； 糖化血色素

並列摘要

Diabetes affects the health conditions of at least 200 million people worldwide, and one person died from diabetes every 10 second around the world; IDF expects that by 2025, the death will increase to 3300 million.In Taiwan, the cause of death statistics announced by the Department of Health, Taiwan in year 98, showed that the diabetic has become the fifth leading cause of death, and accounted for 5.8% of overall mortality (Taiwan Department of Health, 2009); diabetes have become one of chronic diseases so that the bad control of diabetes
would cause many complications. The latest two oral hypoglycemic medicines (Dipeptidyl Peptidase-IV Inhibitor) introduced into Taiwan, the pyrrolidine derivatives, can
inhibit the activity of DPP IV, avoid endogenous GLP-1
(glucagon-likepeptide-1), and the breakdown of GIP (glucose-dependent insulinotropic polypeptide) to reduce high blood sugar, not to affect body weight, and easily to lead to low blood sugar level.

並列關鍵字

Diabetes ； Dipeptidyl Peptidase-IV Inhibitor ； HbA1c

參考文獻

2.2008年國民健康局台灣地區三高追蹤調查報告

1.國際糖尿病聯盟International Diabetes Federation (IDF)

4. American Diabetes Association. Standards of Medical Care in Diabetes—2010.Diabetes Care 2010 33:S11-S61

9.The Diabetes Control and Complications Trial -- Implications for Policy and Practice N Engl J Med. 1993 Sep 30;329(14):1035-6

13.When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study Int J Clin Pract. 2008 Jul;62(7):1013-8. Epub 2008 May